Answers are grounded in this paper and cite their sources.
Trigeminal neuralgia (TN) is a chronic neuropathic pain disorder marked by sudden, severe, and recurrent episodes of facial pain, often refractory to long-term conventional therapies. Plant-derived bioactives with neuromodulatory, antioxidant, and anti-inflammatory potential are increasingly being explored as safer therapeutic alternatives. Acorus calamus, a medicinal plant widely used in traditional systems, exhibits analgesic, anti-inflammatory, and neuroprotective properties; however, its clinical translation is limited by poor aqueous solubility, low oral bioavailability, and rapid systemic metabolism. Nanoemulsion-based formulations provide an efficient platform to overcome these challenges by enhancing solubility, absorption, and sustained release. Chitosan, a natural biodegradable and biocompatible polysaccharide, further improves therapeutic delivery owing to its mucoadhesive properties, ability to facilitate controlled release, and capacity to cross biological barriers. The design of a chitosanbased nanocarrier encapsulating Acorus calamus nanoemulsion could significantly enhance drug stability, prolong systemic circulation, and enable targeted delivery to neural tissues. This approach is expected to improve therapeutic efficacy, reduce dose frequency, and minimize systemic adverse effects in TN management. Such a strategy combines the neuroprotective potential of Acorus calamus with the advanced delivery capabilities of chitosan nanotechnology, presenting a novel, safe, and patient-friendly alternative for effective neuropathic pain therapy.
No takes yet. Share an insight, caveat, or question.
V et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: